49 results about "Monitoring immune" patented technology

The invention is a method for detecting and measuring T-cell receptor (TCR) repertoires from mammalian lymphocytes. The method is based on the use of the multiple sets of unique primers to amplify 22 regions of the TCR Vβ region and thereby detect clonal expansions related to antigen stimulation of the immune system. Kits containing sets of primers and specialized analytical statistical software for use in determining clonal expansion in humans and mice are disclosed. The reliability, efficiency and short assay time in using the method is well suited to monitoring immune response to vaccination and therapeutic treatments for immune disorders.

The present invention relates to methods for identifying compounds that can reduce immune rejection, for example, transplant- or autoimmune disorder-related immune rejection. The present invention is based, in part, on the discovery, demonstrated herein, that immune rejection can be monitored by determining the amount of particular members of the Jak/Stat signal transduction pathway present within an affected tissue. The present invention is further based, in part, on the discovery, demonstrated herein, that immune rejection can be reduced and tolerance can be induced by modulating the amount of these particular members of the Jak/Stat signal transduction pathway present, expressed or active within an affected tissue. In particular, the results demonstrate that immune rejection can be monitored by determining the amount of mRNA or protein of Stat1, Stat3, Stat4, Stat6, SOCS1, or SOCS3 present, e.g., in an affected tissue.

The invention is direct to a method for determining a cancer patient's immune responsiveness to anti-cancer vaccination. In one aspect, for each of a plurality of vaccinations, pairs of clonotype profiles are obtained, one immediately prior to vaccination and one during the period of peak immune response, usually within two to twenty days after the vaccination. Responsiveness is correlated to successive increases in identical clonotypes within each pair of clonotype profiles in at least two successive vaccinations.

The present invention provides a therapeutic method for removing amyloid fibrils from a patient. The present invention also provides a transgenic animal that develops systemic AA amyloidosis within three weeks for use as a tool to investigate AA amyloidosis and to evaluate agents that may be potentially useful in preventing and treating amyloid-related disorders. Further, the present invention provides diagnostic assays for monitoring immunoglobulin light chain fibrillogenesis in real-time and for identification of the chemical nature of the protein in amyloid deposits which enables the determination of the type of amyloidosis for therapeutic and prognostic purposes.

The invention discloses a label-free electrochemical immunosensor for melamine content determination, and a preparation method and application thereof. The immunosensor comprises a substrate electrode, wherein the surface of the substrate electrode is modified by a graphene-melamine-chitosan composite, and nonspecific active sites are sealed by bovine serum proteins. The method for preparing the electrochemical immunosensor is implemented by fixing melamine antigens on the surface of a glass carbon electrode with graphene/chitosan composite materials. Based on an immunoreactive competition mode, the electrochemical immunosensor monitors immune reaction through cyclic voltammetry and differential pulse voltammetry by taking K3Fe(CN)6 as a probe,, and can be used for melamine content detection. The immunosensor disclosed by the invention is high in sensitivity and specificity, simple in detection method and wide in application range; the limit of detection can reach 0.2 ng/ml, and the linear range is 5-1500 ng/ml; and the immunosensor has the characteristics of high speed, high efficiency, high sensitivity, good specificity, simple operation, low cost and the like.

Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment.

The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.

Diagnosis of lung cancer in a subject before onset of symptoms is described herein (i.e., in a pre-diagnostic subject), by screening a biological fluid from the subject for the presence therein of autoantibodies that are specific for one or more pre-diagnostic lung cancer indicator proteins, including LAMR1, and optionally additionally or alternatively including annexin I and/or 14-3-3-theta and/or other pre-diagnostic lung cancer indicator proteins as presently disclosed, as the defined antigens. Related methods, including for monitoring immune reactivity against lung cancer indicator proteins in a lung cancer patient, typing lung cancer subjects or characterizing lung tumors, and application of the described proteomics approach for the identification of additional pre-diagnostic lung cancer indicator proteins, are also contemplated.

The invention provides an indirect ELISA (enzyme-linked immuno-sorbent assay) kit for detecting a nephropathogenic avian infectious bronchitis virus and an antibody thereof, and belongs to the technical field of biology. The indirect ELISA kit for detecting the nephropathogenic avian infectious bronchitis virus and the antibody thereof comprises an ELISA plate which is coated by DS10 monoclonal antibodies resisting the nephropathogenic avian infectious bronchitis virus and is combined with DS10 inactivated purified antigens resisting the nephropathogenic avian infectious bronchitis virus. The indirect kit for detecting the nephropathogenic avian infectious bronchitis virus and the antibody thereof has the advantages of specificity, sensitivity, quickness and simplicity and convenience in operation, and can be used for quickly diagnosing whether chickens are infected by the nephropathogenic avian infectious bronchitis virus or not and monitoring the immune antibody in actual production.

The invention discloses a whole blood type freeze-dried powder immunosuppressant quality control substance as well as a preparation method and application thereof. The substance is a freeze-dried product mainly prepared from human whole blood serving as a matrix and an immunosuppressant. The immunosuppressant comprises one or more of tacrolimus, sirolimus, everolimus and cyclosporin A, or furthercomprises glucocorticoid immunosuppressants: one or more of hydrocortisone, cortisone, prednisolone, prednison and mycophenolic acid ester immunosuppressants for blood detection. The substance has theadvantages that the uniformity and the stability are good, low-temperature storage at -70 DEG C is not needed, and the substance can be used as a calibration product of immunosuppressant kits of different methodologies and can also be used as a quality control product for clinically monitoring an immunosuppressant detection system.

The present invention is related to transplant rejection. In particular, the present invention relates to determining the functional status of alloreactive T cells and correlating the functional status to in vivo immune responses (e.g., tolerance, rejection, or absence of rejection mediated by T cells). The present invention finds use in basic research, clinical (e.g., transplant) and therapeutic settings.

The invention belongs to the field of biotechnology detection, in particular to an F1-protein-based indirect immunofluorescence kit for detecting a type 4 fowl adenovirus antibody. The kit comprises 293T cells expressing F1 protein, an FITC-labeled goat-anti-chicken antibody, a sample diluent and a washing liquid. The kit has good specificity and not only can be used for epidemiological investigation of serum type 4 fowl adenovirus infection conditions, but also can be used for monitoring the level of a serum type 4 fowl adenovirus antibody of immune chicken flocks and used for evaluating the immunoprotecive antibody level.

The invention discloses a detection kit for chicken infectious bronchitis indirect ELISA antibody, belonging to the field of biotechnology. According to the invention, genetically engineered bacterium capable of steadily expressing partial nucleoprotein of chicken infectious bronchitis virus is utilized for inducible expression of recombined N160 protein which is subjected to affinity chromatographic purification, and the purified recombined N160 protein is taken as a coating antigen, so as to establish a simple and convenient and specific indirect ELISA method. The invention further provides a specific, sensitive, quick and convenient-to-operate kit for detecting the antibody of the chicken infectious bronchitis virus, which can be used for quickly diagnosing whether the chicken flocks are infected by the chicken infectious bronchitis virus and monitoring the immune chicken serum antibody level and the chicken maternal antibody level in actual production, so as to evaluate the degree of risk that the chicken flocks are infected by the infectious bronchitis virus and provide reference for the formulation of an infectious bronchitis immune procedure.

The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL⁺ pre B-cell ALL. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring immune disorders, e.g., Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL⁺ pre B-cell ALL.

The invention relates to biomarkers for diagnosing and/or monitoring tuberculosisin both immunocompetent and immunocompromised individuals, monitoring the responses of individuals to anti-mycobacterial chemotherapy, monitoring the progression of latent tuberculosis to active tuberculosis, differentiating active tuberculosis from latent tuberculosis, and from other clinical conditions that mimic tuberculosis (TB). The invention also relates to methods for diagnosing, treating and monitoring tuberculosis using said biomarkers. The above pertain in all aspects both to pulmonary and extrapulmonary Mycobacterium.tuberculosis infections, with Mycobacterium.tuberculosis being the causative organism in tuberculosis.

The present invention provides novel biomarkers for regulatory T cells (Treg) function and Parkinson's disease.

The invention discloses a liquid chromatography-tandem mass spectrometry method and a kit for accurately determining the content of five immunosuppressants in a dry blood spot. The method comprises the following steps: 1) uniformly mixing an internal standard working solution with an organic solvent to obtain an extracting solution; 2) extracting the dry blood spot of the sample to be detected by using the extracting solution, centrifuging to obtain a supernatant I after the extraction is finished, blow-drying the supernatant I with nitrogen, re-dissolving to obtain a solution II, whirling, centrifuging, and detecting; and 3) detecting the solution II by adopting a liquid chromatography-tandem mass spectrometry method, wherein the internal standard working solution contains a cyclosporin A isotope internal standard substance, an everolimus isotope internal standard substance, a sirolimus isotope internal standard substance and a mycophenolic acid isotope mixed internal standard substance. According to the method, during detection, five immunosuppressants can be quantified at a time only by 6 microliters of a blood sample, the pretreatment method is simple and rapid, the operation time is saved, the immunosuppressive blood concentration can be effectively monitored according to the indexes, and more complete treatment medication information can be obtained in time.

The present invention provides a method of monitoring the efficacy of an immunotherapy in a mammalian subject, wherein the subject has been administered an immunotherapy, wherein the immunotherapy comprises a viral vector containing a polynucleotide encoding an antigen, wherein the viral vector is capable of transducing cells in the mammalian subject to cause the cells to express the antigen; the method comprising:

• (b) measuring, from a biological sample isolated from the subject, an immune response of the subject to the antigen and comparing the immune response of the subject to the antigen to a reference measurement of immune response to the antigen;
• (c) measuring, from a biological sample isolated from the subject, an immune response of the subject to the viral vector and comparing the immune response of the subject to the viral vector to a reference measurement of immune response to the viral vector; and
• (d) determining efficacy based on the comparisons of (b) and (c), wherein an elevated immune response to the antigen and a reduced immune response to the viral vector are indicative of an effective immunotherapy.

The present application provides compositions and methods useful for detecting and monitoring immune thrombocytopenia.

The invention generally provides improved compositions and methods for monitoring immune status of a subject. In particular, the invention provides methods for detecting BCMA in subjects to reliably monitor immune status of the subject.